PE20020340A1 - Composicion farmaceutica que comprende ester etilico de acido [2r,4s]-4-[(3,5-bis-trifluorometilbencil)metoxicarbonilamino]-2-etil-6-trifluorometil-3,4-dihidro-2h-quinolina-1-carboxilico y atorvastatina o sus metabolitos hidroxilicos - Google Patents

Composicion farmaceutica que comprende ester etilico de acido [2r,4s]-4-[(3,5-bis-trifluorometilbencil)metoxicarbonilamino]-2-etil-6-trifluorometil-3,4-dihidro-2h-quinolina-1-carboxilico y atorvastatina o sus metabolitos hidroxilicos

Info

Publication number
PE20020340A1
PE20020340A1 PE2001000810A PE2001000810A PE20020340A1 PE 20020340 A1 PE20020340 A1 PE 20020340A1 PE 2001000810 A PE2001000810 A PE 2001000810A PE 2001000810 A PE2001000810 A PE 2001000810A PE 20020340 A1 PE20020340 A1 PE 20020340A1
Authority
PE
Peru
Prior art keywords
ethyl
trifluoromethylbenzyl
atorvastatin
quinoline
dihydro
Prior art date
Application number
PE2001000810A
Other languages
English (en)
Inventor
Charles Lester Shear
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20020340A1 publication Critical patent/PE20020340A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE a) ESTER ETILICO DE ACIDO [2R,4S]-4-[(3,5-BIS-TRIFLUOROMETILBENCIL)METOXICARBONILAMINO]-2-ETIL-6-TRIFLUOROMETIL-3,4-DIHIDRO-2H-QUINOLINA-1-CARBOXILICO; b) ATORVASTATINA O UN COMPUESTO DE FORMULA I O IA DONDE R1 ES H, OH, O UNA DE SUS SALES Y c) VEHICULO FARMACEUTICAMENTE ACEPTABLE. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE ATEROSCLEROSIS, ANGINA DE PECHO, NIVELES ELEVADOS DE COLESTEROL, RIESGO CARDIACO
PE2001000810A 2000-08-15 2001-08-14 Composicion farmaceutica que comprende ester etilico de acido [2r,4s]-4-[(3,5-bis-trifluorometilbencil)metoxicarbonilamino]-2-etil-6-trifluorometil-3,4-dihidro-2h-quinolina-1-carboxilico y atorvastatina o sus metabolitos hidroxilicos PE20020340A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22523800P 2000-08-15 2000-08-15

Publications (1)

Publication Number Publication Date
PE20020340A1 true PE20020340A1 (es) 2002-05-10

Family

ID=22844100

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000810A PE20020340A1 (es) 2000-08-15 2001-08-14 Composicion farmaceutica que comprende ester etilico de acido [2r,4s]-4-[(3,5-bis-trifluorometilbencil)metoxicarbonilamino]-2-etil-6-trifluorometil-3,4-dihidro-2h-quinolina-1-carboxilico y atorvastatina o sus metabolitos hidroxilicos

Country Status (27)

Country Link
US (1) US20020035125A1 (es)
EP (1) EP1309329A2 (es)
JP (1) JP2004506008A (es)
KR (1) KR20030069983A (es)
CN (1) CN1735416A (es)
AP (1) AP2003002743A0 (es)
AU (1) AU2001270937A1 (es)
BG (1) BG107515A (es)
BR (1) BR0113200A (es)
CA (1) CA2419406A1 (es)
CZ (1) CZ2003390A3 (es)
DZ (1) DZ3409A1 (es)
EA (1) EA200300155A1 (es)
EC (1) ECSP034478A (es)
HR (1) HRP20030104A2 (es)
HU (1) HUP0303083A3 (es)
IL (1) IL154348A0 (es)
IS (1) IS6700A (es)
MX (1) MXPA03001419A (es)
NO (1) NO20030725D0 (es)
PA (1) PA8525301A1 (es)
PE (1) PE20020340A1 (es)
SK (1) SK1742003A3 (es)
SV (1) SV2003000600A (es)
TN (1) TNSN01125A1 (es)
UY (1) UY26883A1 (es)
WO (1) WO2002013797A2 (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044459A1 (en) * 2001-09-04 2003-03-06 Pfizer Inc. Biomodulated multiparticulate formulations
US7071210B2 (en) 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
MXPA05005813A (es) 2002-12-20 2005-12-12 Pfizer Prod Inc Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa.
ATE389396T1 (de) * 2002-12-20 2008-04-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
UA82698C2 (uk) * 2003-05-30 2008-05-12 Ранбакси Лабораториз Лимитед Заміщені похідні піролу та їх використання в якості інгібіторів hmg-co
MXPA06001506A (es) * 2003-08-04 2006-05-15 Pfizer Prod Inc Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa.
KR20070087197A (ko) 2003-09-26 2007-08-27 니뽄 다바코 산교 가부시키가이샤 잔여 리포프로테인 생산 저해 방법
CA2562082C (en) * 2004-04-13 2013-06-25 Merck & Co., Inc. Cetp inhibitors for the treatment and prevention of atherosclerosis
WO2006082500A1 (en) * 2005-02-03 2006-08-10 Pfizer Products Inc. Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP2334295B1 (en) 2008-09-02 2017-06-28 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
AU2010213899B2 (en) 2009-02-10 2014-02-06 Amarin Pharmaceuticals Ireland Limited Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
US11033523B2 (en) 2009-04-29 2021-06-15 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
SG10201708952TA (en) 2009-06-15 2017-12-28 Ian Osterloh Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc COMPOSITION WITH LOW IMPACT EFFECT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES IN A PATIENT WITH FISH ALLERGY / SENSITIVITY
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
LT3363433T (lt) 2012-06-29 2021-02-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos sutrikimų rizikos sumažinimo būdas subjektui, gydomam statinais, panaudojant eikozapentaeno rūgšties etilo esterį
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
SG11202102872QA (en) 2018-09-24 2021-04-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of cardiovascular events in a subject
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
AU2157400A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method

Also Published As

Publication number Publication date
CZ2003390A3 (en) 2004-03-17
MXPA03001419A (es) 2003-06-06
AP2003002743A0 (en) 2003-03-31
IS6700A (is) 2003-01-27
HRP20030104A2 (en) 2003-04-30
SK1742003A3 (en) 2004-06-08
ECSP034478A (es) 2003-03-31
CN1735416A (zh) 2006-02-15
DZ3409A1 (fr) 2002-02-21
CA2419406A1 (en) 2002-02-21
WO2002013797A3 (en) 2003-03-13
US20020035125A1 (en) 2002-03-21
UY26883A1 (es) 2002-03-22
IL154348A0 (en) 2003-09-17
NO20030725D0 (no) 2003-02-14
KR20030069983A (ko) 2003-08-27
HUP0303083A3 (en) 2005-05-30
PA8525301A1 (es) 2002-04-25
JP2004506008A (ja) 2004-02-26
HUP0303083A2 (hu) 2003-12-29
TNSN01125A1 (fr) 2005-11-10
WO2002013797A2 (en) 2002-02-21
AU2001270937A1 (en) 2002-02-25
EP1309329A2 (en) 2003-05-14
EA200300155A1 (ru) 2003-08-28
BG107515A (en) 2003-09-30
BR0113200A (pt) 2003-09-16
SV2003000600A (es) 2003-01-13

Similar Documents

Publication Publication Date Title
PE20020340A1 (es) Composicion farmaceutica que comprende ester etilico de acido [2r,4s]-4-[(3,5-bis-trifluorometilbencil)metoxicarbonilamino]-2-etil-6-trifluorometil-3,4-dihidro-2h-quinolina-1-carboxilico y atorvastatina o sus metabolitos hidroxilicos
PE20030128A1 (es) Formulaciones autoemulsionantes de inhibidores de la proteina de transferencia de colesteril ester
DE69830504D1 (de) Antithrombotische mitteln
DE69831868D1 (en) Antithrombosemittel
AR036331A1 (es) Compuestos utiles como intermediarios en la elaboracion de inhibidores de cetp y procedimiento para obtener dichos intermediarios e inhibidores
IS4695A (is) (Metýlsúlfónýl)fenýl-2-(5H)-fúranón sem sýklóoxýgenasa-2 tálmar
PE20071150A1 (es) Un proceso para preparar derivados de tetrahidroquinolina
CA2213036A1 (en) Stabilization of an unstable retinoid in oil-in-water emulsions for skin care compositions
KR930016393A (ko) 비아릴 치환된 4-아미노-부티르산 아미드, 이의 제조방법 및 이를 함유하는 약제학적 조성물
ES2138626T3 (es) Acidos (3r,4r)-delta6-tetrahidrocannabinol-7-oicos.
MX9207152A (es) Composiciones farmaceuticas estabilizadas que comprenden un compuesto inhibidor de la hmg-coa reductasa y metodo para su preparacion.
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
AR079399A2 (es) Procedimientos para preparar bifenazato
BR0307801A (pt) Processo para a fabricação de derivados de ácido mevalÈnico inibidores da hmg-coa reductase
BR0109048A (pt) Processo para a sìntese de citalopram
BR9710911A (pt) Um processo para a formação de um perácido e uma composição compreendendo o perácido referido.
BR0210266A (pt) Composição farmacêutica que compreende um inibidor de lìpases, processo para preparar essa composição, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
DK0577040T3 (da) Fremgangsmåde til fremstilling af (3R,5S)6-hydroxy-3,,5-O-isopropyliden-3,5-dihydroxyhexansyre-tert.-butylester
DE69430538D1 (de) 2-azylalkyl-oder arylalenyl-cyclopentanheptan-und heptensäuren, derivate und therapeutische anwendung
KR970074763A (ko) 불소화된 비타민 d₃ 유사체
EP1219288A3 (en) Treatment for skin
DE69923332D1 (de) Rückfettende ester auf basis von capryl-alkohol und isostearinsäure
ATE45738T1 (de) 1-cyclopropyl-1,4-dihydro-4-oxo-7-(4-(2-oxo-1,3 dioxol-4-yl-methyl)-1-piperazinyl>-3chinolincarbons|uren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel.
ATE295165T1 (de) Mittel zur adjuvanten therapie von demenzen enthaltend alpha-liponsäure
AR008993A1 (es) Sales de esteres etilicos de acidos 3-(2-(4-(4-(amino-imino-metil)-fenil)-4 -metil-2,5-dioxo-imidazolidin-1-il)-acetilamino)-3-fenil-propionicos

Legal Events

Date Code Title Description
FD Application declared void or lapsed